Gensight BiologicsGSGTF EBIT per Share is $-0.08 as of Dec. 2025. The stock has 8 warning signs investors should review. Among 1,180 Biotechnology companies, Gensight Biologics ranks better than 86.02% on this metric.
Gensight Biologics's EBIT per Share for the
six
months ended in Dec. 2025 was $-0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.08.
During the past 3 years, the average EBIT per Share Growth Rate was 50.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 35.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 21.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Gensight Biologics's EBIT per Share or its related term are showing as below:
GSGTF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -86.5 Med: 10.5 Max: 50
Current: 50
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Gensight Biologics was 50.00% per year. The lowest was -86.50% per year. And the median was 10.50% per year.
GSGTF's 3-Year EBIT Growth Rate is ranked better than 86.02% of 1180
companies
in the Biotechnology industry
Industry Median: 15.55
vs GSGTF: 50.00
Gensight Biologics (OTCPK:GSGTF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Gensight Biologics EBIT per Share Related Terms
Gensight Biologics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Gensight Biologics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gensight Biologics (GSGTF) has a EBIT per Share of $-0.08 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Gensight Biologics and its competitors. According to the industry distribution chart, Gensight Biologics ranks #165 out of 1180 companies in the Biotechnology industry, placing it in the top 14%.
Is Gensight Biologics' EBIT per Share too high?
Gensight Biologics' current EBIT per Share is $-0.08. Based on the distribution chart, Gensight Biologics ranks #165 out of 1180 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Gensight Biologics' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #165 out of 1180 companies for EBIT per Share. This places Gensight Biologics in the top 14% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,180 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Gensight Biologics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gensight Biologics's current EBIT per Share is $-0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (GSGTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.09 — trading 125% above its estimated fair value. The current EBIT per Share is $-0.08. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current EBIT per Share is $-0.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GSGTF has been successfully added to your 